SCHEMBL23116281

SCHEMBL23116281

Cc1nc2nc(C)c(CC3CCN(c4ccc(Br)cc4)C3)c(C)n2n1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC16A3 O15427 7/20 0.61
KCNH2 Q12809 4/20 0.61
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
MAPT P10636 2/20 0.37
KDM4E B2RXH2 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
SLC6A2 P23975 2/20 0.36
SLC6A4 P31645 2/20 0.36
LMNA P02545 2/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C19 P33261 1/20 0.35
GAA P10253 1/20 0.34
THRB P10828 1/20 0.34
ALDH1A1 P00352 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21565558 1.00 SLC16A3 (0.61) SLC16A3KCNH2MEN1KMT2AMAPT
SCHEMBL21550815 0.89 SLC16A3 (0.62) SLC16A3KCNH2MEN1KMT2AMAPT
SCHEMBL21550817 0.89 SLC16A3 (0.62) SLC16A3KCNH2MEN1KMT2AMAPT
SCHEMBL29725189 0.89 SLC16A3 (0.62) SLC16A3KCNH2MEN1KMT2AMAPT
SCHEMBL21555643 0.89 SLC16A3 (0.61) SLC16A3KCNH2MEN1KMT2AMAPT
SCHEMBL21555642 0.89 SLC16A3 (0.61) SLC16A3KCNH2MEN1KMT2AMAPT
SCHEMBL21557902 0.87 SLC16A3 (0.59) SLC16A3KCNH2MEN1KMT2AMAPT
SCHEMBL21557901 0.87 SLC16A3 (0.59) SLC16A3KCNH2MEN1KMT2AMAPT
SCHEMBL21551528 0.85 SLC16A3 (0.59) SLC16A3KCNH2MEN1KMT2AMAPT
SCHEMBL21551527 0.85 SLC16A3 (0.59) SLC16A3KCNH2MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503473-B2 Triazolopyrimidine compounds and their use in treating cancer DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2025-12-23 US disclosed
US-20240217980-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2024-07-04 US disclosed
CN-115028637-B Triazolopyrimidine compounds and their use for the treatment of cancer 迪哲(江苏)医药股份有限公司 2024-03-22 CN disclosed
US-11851432-B2 Triazolopyrimidine compounds and their use in treating cancer DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2023-12-26 US disclosed
EP-4134368-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2023-02-15 EP disclosed
CN-115028637-A Triazolopyrimidine compounds and their use for the treatment of cancer 迪哲(江苏)医药股份有限公司 2022-09-09 CN disclosed
CN-115028636-A Triazolopyrimidine compounds and their use for the treatment of cancer 迪哲(江苏)医药股份有限公司 2022-09-09 CN disclosed
EP-3790879-B1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2022-06-29 EP disclosed
CN-112469721-B Triazolopyrimidine compounds and their use for the treatment of cancer 迪哲(江苏)医药股份有限公司 2022-06-07 CN disclosed
US-20210340150-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2021-11-04 US disclosed
US-11084827-B2 Triazolopyrimidine compounds and their use in treating cancer DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2021-08-10 US disclosed
US-20210087196-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2021-03-25 US disclosed
CN-112469721-A Triazolopyrimidine compounds and their use for the treatment of cancer 迪哲(江苏)医药股份有限公司 2021-03-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12503473-B2 Triazolopyrimidine compounds and their use in treating cancer ABCC4, ABCB1, SLC16A3 SLC16A3 3/4885KCNH2 410/4885MEN1 3154/4885
US-11084827-B2 Triazolopyrimidine compounds and their use in treating cancer ABCC4, ABCB1, SLC16A3 SLC16A3 3/4885KCNH2 410/4885MEN1 3154/4885
US-20210087196-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER ABCC4, ABCB1, SLC16A3 SLC16A3 3/4885KCNH2 410/4885MEN1 3154/4885
US-20210340150-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER ABCC4, ABCB1, SLC16A3 SLC16A3 3/4885KCNH2 410/4885MEN1 3154/4885
US-20240217980-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER ABCC4, ABCB1, SLC16A3 SLC16A3 3/4885KCNH2 410/4885MEN1 3154/4885
US-11851432-B2 Triazolopyrimidine compounds and their use in treating cancer ABCC4, ABCB1, SLC16A3 SLC16A3 3/4885KCNH2 410/4885MEN1 3154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.